wow-inequalities/02-data/intermediate/wos_sample/25531df44e10c9c30e5be3673d585e8e-calderon-auaricio-a/info.yaml

105 lines
3.4 KiB
YAML
Raw Normal View History

2023-09-28 14:46:10 +00:00
abstract: 'Background: Anti-cancer cytotoxic treatments like platinum-derived
compounds often show low therapeutic efficacy, high-risk side effects
and resistance. Hence, targeted treatments designed to attack only
tumour cells avoiding these harmful side effects are highly needed in
clinical practice. Due to this, precision oncology has arisen as an
approach to specifically target alterations present only in cancer
cells, minimising side effects for patients. It involves the use of
molecular biomarkers present in each kind of tumour for diagnosis,
prognosis and treatment. Since these biomarkers are specific for each
cancer type, physicians use them to stratify, diagnose or take the best
therapeutic options for each patient depending on the features of the
specific tumour.
Aim: This review aims to describe the current situation, limitations,
advantages and perspectives about precision oncology in Latin America.
Main body: For many years, many biomarkers have been used in a clinical
setting in developed countries. However, in Latin American countries,
their broad application has not been affordable partially due to
financial and technical limitations associated with precarious health
systems and poor access of low-income populations to quality health
care. Furthermore, the genetic mixture in Latin American populations
could generate differences in treatment responses from one population to
another (pharmacoethnicity) and this should be evaluated before
establishing precision therapy in particular populations. Some research
groups in the region have done a lot of work in this field and these
data should be taken as a starting point to establish networks oriented
to finding clinically useful cancer biomarkers in Latin American
populations.
Conclusion: Latin America must create policies allowing excluded
populations to gain access to health systems and next generation
anti-cancer drugs, i.e. high-cost targeted therapies to improve
survival. Also, cancer clinical research must be oriented to establish
cancer biomarkers adapted to specific populations with different
ethnicity, allowing the improvement of patient outcomes.'
affiliation: 'Orue, A (Corresponding Author), IVIC, Ctr Microbiol, Tumor Cell Biol
Lab, Caracas 1020A, Venezuela.
Calderon-Auaricio, Ali; Orue, Andrea, IVIC, Ctr Microbiol, Tumor Cell Biol Lab,
Caracas 1020A, Venezuela.'
article-number: '920'
author: Calderon-Auaricio, Ali and Orue, Andrea
author-email: andreaorue@gmail.com
author_list:
- family: Calderon-Auaricio
given: Ali
- family: Orue
given: Andrea
da: '2023-09-28'
doi: 10.3332/ecancer.2019.920
files: []
issn: 1754-6605
journal: ECANCERMEDICALSCIENCE
keywords: 'precision oncology; biomarkers; cancer; targeted therapy; access to
health care; Latin America'
keywords-plus: 'CELL LUNG-CANCER; ANDROGEN RECEPTOR; PERSONALIZED MEDICINE; OPEN-LABEL;
METHYLATION; EPIGENOMICS; MUTATIONS; THERAPY; DRUGS; EGFR'
language: English
month: APR 3
number-of-cited-references: '78'
orcid-numbers: Calderon-Aparicio, Ali/0000-0003-0656-1434
papis_id: fc9d7da5e3f031b464597b9888d132ba
ref: Calderonauaricio2019precisiononcology
times-cited: '7'
title: 'Precision oncology in Latin America: current situation, challenges and perspectives'
2023-10-01 08:15:07 +00:00
type: article
2023-09-28 14:46:10 +00:00
unique-id: WOS:000464006000001
usage-count-last-180-days: '0'
usage-count-since-2013: '2'
volume: '13'
web-of-science-categories: Oncology
year: '2019'